Astrea Bioseparations invests in infrastructure in UK and Singapore

The company has expanded its R&D facility in Cambridge, UK, and registered a branch office in Singapore

Image credit: Astrea Bioseparations

Astrea Bioseparations, a provider of bioseparations products and services, has announced two investments to enhance its operations and customer support resources. The investments include an expansion of the company’s R&D facility in Cambridge, UK to add two laboratories.

Separately, a branch office was registered in Singapore to serve customers in Asia with Claire Dacombe, PhD appointed as VP of Asia Pacific Operations.

“The Cambridge laboratory expansion was a first step in bolstering capacity to meet growing demand for Astrea Bioseparations products and services. New dedicated column packing space was constructed to increase capacity for pre-packed column development and support,” said Dr Steve Burton, President & CSO at Astrea. “A new Biosafety Level 2 (BSL-2) laboratory has facilitated work with pathogenic materials of relevance for viral vector, virus and prion projects. Pursuant to the December 2020 license agreement with Avacta, we have also dedicated new laboratory space for Affimer ligand discovery and development work.”

“This is an exciting time as we continue to evolve our commercial strategy with a focus on reliability of supply and quality of products and services. With market demand increasing in Asia, it became clear that it would benefit our customers to have a local presence in Singapore,” Gabe Longoria, CCO said. “We are thrilled to have Claire Dacombe join Astrea Bioseparations with extensive expertise in high level distribution, sales, and operations activities across the Asia Pacific region.”

The company’s team invites attendees of Bioprocess International to visit booth 334 in Boston, MA from 21 to 30 September.

Companies